Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

United Therapeutic (UTHR)

United Therapeutic (UTHR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

United Therapeutic 1000 SPRING ST SILVER SPRING MD 20910 USA

www.unither.com P: 301-608-9292 F: 301-608-9291

Description:

United Therapeutics Corporation markets four medicines in the United States to treat pulmonary arterial hypertension (PAH): Remodulin, an injectable formulation of treprostinil, Orenitram, an oral version of treprostinil, Tyvaso, an inhaled version of treprostinil, and Adcirca (tadalafil; also sold by Eli Lilly as Cialis for erectile dysfunction) tablets.

Key Statistics

Overview:

Market Capitalization, $K 11,800,911
Enterprise Value, $K 11,293,211
Shares Outstanding, K 44,356
Annual Sales, $ 2,328 M
Annual Net Income, $ 984,800 K
Last Quarter Sales, $ 677,700 K
Last Quarter Net Income, $ 306,600 K
EBIT, $ 1,257 M
EBITDA, $ 1,310 M
60-Month Beta 0.54
% of Insider Shareholders 12.50%
% of Institutional Shareholders 94.08%
Float, K 38,811
% Float 87.50%
Short Volume Ratio 0.63

Growth:

1-Year Return 24.51%
3-Year Return 34.46%
5-Year Return 193.49%
5-Year Revenue Growth 42.98%
5-Year Earnings Growth 47.95%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 6.17 on 05/01/24
Latest Earnings Date N/A
Earnings Per Share ttm 21.15
EPS Growth vs. Prev Qtr 41.51%
EPS Growth vs. Prev Year 26.95%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 2-1 on 09/23/09

UTHR Ratios

Ratio
Price/Earnings ttm 12.34
Price/Earnings forward 11.00
Price/Earnings to Growth N/A
Return-on-Equity % 18.72%
Return-on-Assets % 15.35%
Profit Margin % 42.31%
Debt/Equity 0.11
Price/Sales 4.98
Price/Cash Flow 12.05
Price/Book 2.21
Book Value/Share 120.31
Interest Coverage 22.49
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar